The observed prevalence of HER2 gene amplification in the primary tumor tissue of GC patients were in the same range, which has been found in a FISH-based study reported in 2002 by Takehana et al.[24] who found HER2 amplification in approximately 8% of the cases. This evidence concerns the gene ERBB2 and gastric cancer.